NasdaqGS:ALMSPharmaceuticals
The Bull Case For Alumis (ALMS) Could Change Following Envudeucitinib Phase 3 Data And New Equity Plans - Learn Why
Alumis reported full-year 2025 results showing US$24.05 million in revenue and a net loss of US$243.33 million, while also filing a universal shelf registration and a US$300 million at-the-market follow-on equity offering alongside positive Phase 3 topline data for its TYK2 inhibitor envudeucitinib in plaque psoriasis.
By pairing encouraging late-stage clinical data and plans for a 2026 New Drug Application with expanded financing flexibility, Alumis is signaling a push to advance...